Opthea Advances nAMD Treatment with Sozinibercept
Company Announcements

Opthea Advances nAMD Treatment with Sozinibercept

Opthea Limited Sponsored ADR (OPT) has released an update.

Opthea Limited Sponsored ADR is making strides in the treatment of neovascular age-related macular degeneration (nAMD) by focusing on the VEGF-C and -D pathways. At the EURetina Symposium 2024, the company highlighted sozinibercept, a novel anti-VEGF-C & -D inhibitor, as an emerging therapy with the potential to set a new standard in visual outcomes. Despite the evolution of treatments targeting the VEGF pathway, there remains a significant portion of patients with suboptimal responses, indicating a strong need for innovative solutions like sozinibercept.

For further insights into OPT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskOpthea Limited Strengthens Leadership and Advances AMD Treatment
TheFlyOpthea executive director Megan Baldwin to retire from board
TipRanks Auto-Generated NewsdeskOpthea Advances Retinal Disease Treatments
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App